Decibel Therapeutics Valuation

DBTXDelisted Stock  USD 3.08  0.02  0.65%   
At this time, the firm appears to be overvalued. Decibel Therapeutics shows a prevailing Real Value of $2.95 per share. The current price of the firm is $3.08. Our model computes the value of Decibel Therapeutics from reviewing the firm fundamentals such as Current Valuation of 62.95 M, shares outstanding of 25.13 M, and Shares Owned By Insiders of 13.35 % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
3.08
Please note that Decibel Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Decibel Therapeutics is based on 3 months time horizon. Increasing Decibel Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Decibel Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Decibel Stock. However, Decibel Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  3.08 Real  2.95 Hype  3.08
The intrinsic value of Decibel Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Decibel Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
2.95
Real Value
3.39
Upside
Estimating the potential upside or downside of Decibel Therapeutics helps investors to forecast how Decibel stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Decibel Therapeutics more accurately as focusing exclusively on Decibel Therapeutics' fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimatedHigh
3.083.083.08
Details

Decibel Therapeutics Total Value Analysis

Decibel Therapeutics is currently anticipated to have valuation of 62.95 M with market capitalization of 127.14 M, debt of 14.05 M, and cash on hands of 125.65 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Decibel Therapeutics fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
62.95 M
127.14 M
14.05 M
125.65 M

Decibel Therapeutics Asset Utilization

One of the ways to look at asset utilization of Decibel is to check how much profit was generated for every dollar of assets it reports. Decibel Therapeutics shows a negative utilization of assets of -0.33 percent, losing $0.003265 for each dollar of assets held by the firm. Unsuccessful asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Decibel Therapeutics shows how unproductive it operates for each dollar spent on its assets.

Decibel Therapeutics Ownership Allocation

Decibel Therapeutics holds a total of 25.13 Million outstanding shares. Over half of Decibel Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Decibel Therapeutics Profitability Analysis

Net Loss for the year was (63.01 M) with profit before overhead, payroll, taxes, and interest of 0.

About Decibel Therapeutics Valuation

Our relative valuation model uses a comparative analysis of Decibel Therapeutics. We calculate exposure to Decibel Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Decibel Therapeutics's related companies.
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. Decibel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 62 people.

Decibel Therapeutics Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares Outstanding25 M
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Consideration for investing in Decibel Stock

If you are still planning to invest in Decibel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Decibel Therapeutics' history and understand the potential risks before investing.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Bonds Directory
Find actively traded corporate debentures issued by US companies
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences